IDH1 and glioblastoma: Given that de novo RRD glioblastomas have a unique genomic and epigenomic landscape and immune cell microenvironment, we therefore sought to determine the clinical outcomes for affected patients and speculated that it might be different than conventional IDH-wildtype glioblastoma.